Arcs are curved lines connecting two countries and represent bilateral agreements or unilateral reliance pathways. Color indicates the agreement category. Solid lines mark active agreements; dashed lines indicate expired agreements or those still under negotiation.
Small arrows along arcs indicate direction of regulatory reliance. For unilateral agreements, arrows point from the relying country (A) toward the reference authority (B) whose assessments it draws on. Mutual agreements have no directional arrows.
Country fills (colored shading) show membership in multilateral agreements. When a multilateral agreement passes the current filters, all member countries are shaded in the corresponding category color.
Category Colors
Interacting with the Map
Use the filter panel on the left to narrow by country, agreement category, year range, or status.
Hover over an arc for a quick summary of the agreement. Hover over a country to see its name and agreement count.
Click on an arc to open a detail panel with the full agreement description and source link. Click on a country to filter the map to that country and see all its agreements listed.
EU agreements present a special case: the arc connects to Amsterdam (EMA) or Brussels (EU institutions), and all 27 EU member states highlight simultaneously.
Agreement Categories
Centralized Procedure
Registration system where a single application is assessed by one body and the resulting marketing authorization is valid across all member states of the region or bloc. Distinct from harmonization (shared standards, separate national reviews) and recognition (accepting another authority's decision post hoc). Used by the EU (via EMA) and the GCC (via the Gulf Health Council). Note: GCC decisions function as recommendations per WHO TRS 1033, Section 5.5, though in practice GCC registration is valid across all 6 member states. In the EU model, the centralized procedure produces a single marketing authorization binding on all 27 member states.
Confidentiality Arrangement (also: Confidentiality Commitment)
Legal framework allowing regulatory authorities to share non-public information, including commercially confidential data, unredacted inspection reports, and patient-level safety data. Prerequisite for substantive regulatory cooperation beyond publicly available assessment reports. FDA uses the term "Confidentiality Commitment" (CC); EMA uses "Confidentiality Arrangement" (CA). Subcategory of Enabling Agreement.
Coordination Body
International organizations and networks that coordinate regulatory activities, share information, and develop common approaches without themselves making approval decisions. Examples include ICMRA, IPRP, PIC/S, ICH, and ICDRA. Their membership indicates how connected a regulator is to the global network.
Enabling Agreement
Framework agreements that facilitate future regulatory cooperation, such as confidentiality arrangements and information-sharing memoranda. Without these, regulators cannot share commercially confidential data or patient-level safety information needed for substantive cooperation.
Harmonization
Alignment of technical requirements, guidelines, and standards across jurisdictions to reduce regulatory divergence. Creates shared requirements so a single dossier can satisfy multiple regulators, but each authority still conducts its own review. Examples include ICH guidelines and PIC/S GMP standards. In some regional harmonization systems, a centralized procedure exists where a single body assesses applications on behalf of all member states and the resulting authorization is valid across the region. Examples include the EU centralized procedure (EMA) and the GCC centralized drug registration. Note: the EAEU uses mutual recognition and decentralized procedures rather than a centralized procedure.
Joint Assessment
Work-sharing mechanism where the same application is submitted simultaneously to two or more NRAs, which divide review modules among themselves (e.g., quality, non-clinical, clinical) and share their scientific assessments. Participating NRAs combine their lists of questions to the manufacturer and base their respective independent regulatory decisions on the outcome of these assessments. Used by ZAZIBONA, EAC-MRH, ECOWAS-MRH, and ASEAN.
Mutual Recognition Agreement (MRA)
Bilateral or multilateral agreement where regulatory authorities formally accept each other's inspection results and/or regulatory assessments. Requires prior demonstration that both systems produce equivalent outcomes. In pharmaceuticals, MRAs typically cover GMP inspections rather than marketing authorizations.
Recognition
Formal acknowledgment of another regulatory authority's standards, processes, or approval decisions. Goes further than reliance: a regulator routinely accepts another's decision with no additional substantive assessment. Rare between sovereign states due to the trust and legal compatibility required.
Reliance Pathway
A structured process where one regulatory authority uses another's assessment as the basis for its own regulatory decision, without conducting a full independent review. The relying authority retains sovereignty and final decision-making responsibility. Can be unilateral (one direction) or mutual.
Work-sharing
Cooperative arrangements where regulatory authorities divide assessment workload and share the results, reducing duplication. All participating authorities actively conduct portions of the review in parallel, distinguishing this from reliance where one authority defers. Examples include the ACCESS Consortium and Project Orbis.
Name
Category
Year
Status
Parties
About This Project
This is a research project mapping the landscape of international pharmaceutical regulatory agreements and cooperation mechanisms. The visualization presents how drug regulatory authorities around the world formalize cooperation through mutual recognition agreements, reliance pathways, harmonization initiatives, and other mechanisms.
These agreements shape how medicines are evaluated and approved globally. They can reduce duplication of regulatory effort, accelerate patient access to medicines, and enable resource-constrained authorities to leverage the expertise of established agencies.
The map draws on publicly available information from regulatory authorities, international organizations, and published literature. It is maintained as part of ongoing research at the intersection of regulatory science, international governance, and policy.
This project is produced by ARB Research with support from Emergent Ventures.
This map was built through iterative "vibe coding" with Claude Opus (Anthropic), where the entire codebase — data, visualization, and text — was generated and refined through conversational prompting rather than traditional software development.
Data accuracy was managed through a multi-agent team pipeline. For each round of additions, independent fact-checker agents verified every agreement's year, parties, regulatory function, and category assignment against primary sources, while a separate data-drafter agent structured entries from coverage reports. A cross-review agent then reconciled the drafted data against the verified facts, flagging discrepancies — this process caught two incorrect years, two miscategorized agreements, and a misdescribed regulatory mechanism before they reached the map. Glossary definitions were verified line-by-line against a local copy of the WHO TRS 1033 Annex 10. A final red-team review verified structural integrity and rendering correctness.
Despite this process, errors in agreement details, categorization, or coverage gaps may remain. Corrections and omissions can be reported to connect@sapien.institute.